Remepy
Remepy develops AI-powered digital treatment protocols that combine with traditional drugs to create hybrid therapies. The New York-based biotech startup has raised $51M in Series A funding and employs 82 people.
The growth story
Remepy grew from 7 to 82 employees between 2022 and 2026, raising $51M along the way, most recently a Series A in August 2026.
About
Remepy creates software-based treatment protocols called Digital Molecules that integrate with pharmaceutical drugs to form hybrid therapies. These AI-driven protocols are personalized for each patient and medical condition, aiming to enhance brain function and balance.
The company has grown to 82 employees since its 2022 founding and secured $51M in Series A funding in August 2026. Its investor base includes notable firms like NFX, M Ventures, and 97212 Ventures.
Founders and leadership
Engineering is Remepy's largest function with 8 employees. The company has a median tenure of 2 years across its workforce.
Departments, and which ones grew
Headcount by function: Engineering 12 (+33% YoY), Entrepreneurship 7 (0% YoY), Healthcare Services 7 (+40% YoY), Program and Project Management 7 (+133% YoY), Research 7 (+75% YoY), Business Development 6 (-14% YoY).
Talent flow
Remepy draws talent primarily from Israeli institutions, with Tel Aviv University (16 alumni) and The Hebrew University of Jerusalem (7 alumni) as top sources. Many employees have backgrounds at Kaltura (7) and Israeli military organizations.
Most common previous employers of Remepy staff: Kaltura (7), Tel Aviv University (6), Israel Defense Forces (5), Israeli Military Intelligence (4), NeuroDerm (3), The Hebrew University of Jerusalem (2). Former Remepy employees most often moved to Sponja (2), OptoRhythm (1), Fresh Fund (1), Sygnia (1), PharmStars Ventures (1), Walmart Global Tech (1).
Alumni worth knowing
The Remepy mafia
Remepy alumni have founded 3 companies, including PharmStars Ventures and Sponja. These startups employ 9 people collectively.
4Naomi Fried, Ph.D., was Advisory Board Member until 2024Yaki Eidelstein, PhD, MBA, was VP Scientific Affairs until 2023Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Remepy: Management (18), Startups (15), Java (14), Life Sciences (13), Research Skills (13), Product Management (12), Biotechnology (12), Software Development (11).
Where the team actually sits
Remepy people are concentrated in Israel (26), Tel Aviv District, Israel (21), New York, United States (3), United Kingdom (1).
Search footprint
Remepy attracts about 9 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 2 ranking keywords and lost 3 in the last period.
Frequently asked
Remepy has 82 employees as of September 2026.
Remepy has raised $51M in total, most recently a Series A round in August 2026.
Remepy was founded in 2022 by Amir Amedi, Michal Tsur, Or Shoval, Eran Etam.
The most common previous employers of current Remepy staff are Kaltura (7 people), Tel Aviv University (6 people), Israel Defense Forces (5 people).
Former Remepy employees most often move to Sponja (2), OptoRhythm (1), Fresh Fund (1).
At least 3 companies have a founder who previously worked at Remepy, including PharmStars Ventures, Sponja, OptoRhythm.
Remepy attracts about 9 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among Remepy staff are Management, Startups, Java, Life Sciences, Research Skills.
Remepy staff are concentrated in Israel (26), Tel Aviv District, Israel (21), New York, United States (3).
Remepy has about 12 people in Engineering, up 33% over the past year, as of September 2026.
Remepy has about 7 people in Entrepreneurship, up 0% over the past year, as of September 2026.
Computed from 55 current and 24 former Remepy profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.